CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

How Biotech Startups can Mitigate...

Vivid Microscopy Detects Early Stages of Heart Disease Using an Animal Model

Vivid Microscopy Detects Early Stages...

How Contract Manufacturing Benefitting Small Businesses

How Contract Manufacturing...

Top Biotech Industry Trends to Watch for in 2022

Top Biotech Industry Trends to Watch...

European Life Sciences Off to a New Beginning

European Life Sciences Off to a New...

Encore Healthcare's VP of Clinical Operations Carrie Hylton-Proffitt, RRT Earns Accreditation with ACHC

Encore Healthcare's VP of Clinical...

Challenges Facing Biotech Companies Seeking Funding

Challenges Facing Biotech Companies...

How are Advancements in Biotechnology Help People Improve their Lives?

How are Advancements in Biotechnology...

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

How Biotech Startups can Mitigate...

Vivid Microscopy Detects Early Stages of Heart Disease Using an Animal Model

Vivid Microscopy Detects Early Stages...

How Contract Manufacturing Benefitting Small Businesses

How Contract Manufacturing...

Top Biotech Industry Trends to Watch for in 2022

Top Biotech Industry Trends to Watch...

European Life Sciences Off to a New Beginning

European Life Sciences Off to a New...

Encore Healthcare's VP of Clinical Operations Carrie Hylton-Proffitt, RRT Earns Accreditation with ACHC

Encore Healthcare's VP of Clinical...

Challenges Facing Biotech Companies Seeking Funding

Challenges Facing Biotech Companies...

How are Advancements in Biotechnology Help People Improve their Lives?

How are Advancements in Biotechnology...

Sporos Bioventures Raises $38.1 Million in Series A Financing

Life Sciences Review Life Sciences Review | Monday, May 17, 2021
Tweet

Sporos Bioventures made its launch official with the close of a $38.1 million Series A financing.


FREMONT, CA: Sporos Bioventures, LLC (the Company or Sporos) made its launch official with the close of a $38.1 million Series A financing. The organization was formed by a group of biotech executives, entrepreneurs, academic scholars, and investors to catalyze the fast and effective development of innovative therapies targeting unique disease mechanisms in cancer and immune diseases. Sporos seeks to bring new hope to patients in a more effective and impactful manner by leveraging its extensive array of industry leaders, strategic resources, and operational expertise. In addition to Series A, Michael Wyzga, M.B.A., former Genzyme CFO, joins the team as Founding CFO.


"Sporos was founded to accelerate the development of new medicines by addressing inefficiencies and risk in the establishment of new biotech companies," said Peter Feinberg, Sporos co-founder and member of the board of directors. "By leveraging our extensive network, including the Texas Medical Center, which is the world's largest research and medical ecosystem, we first identify transformative scientific opportunities and then deploy our top-tier talent, funding and operational support to drive these insights into a growing pipeline of first-in-class treatment options."


Sporos begins with four entities, each based on truly novel mechanisms governing cancer and immune disease. The organization intends to use the Series A proceeds to support the development of lead assets across the Sporos portfolio and expand the Sporos team.


Tvardi, Sporos' most advanced company, is working on small molecule inhibitors of STAT3, a major regulatory protein involved in cancer cell survival and immune evasion, and the pathogenesis of several inflammatory and fibrotic diseases. TTI-101, Tvardis' lead asset in cancer, has been shown in initial clinical studies to be well accepted and to have clinical activity across a wide range of tumours, such as multiple durable responses.


"By strategically deploying valuable resources to young companies that would not typically be supported by top-tier seasoned talent and infrastructure, we believe that we can efficiently bring a diverse set of therapies through clinical development," said Mr Wyzga. "I am thrilled to join a team with decades of scientific and operational expertise and look forward to guiding our strategic and financial growth."


Weekly Brief

loading
Top 10 Biotech Startups Companies - 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/sporos-bioventures-raises-381-million-in-series-a-financing--nwid-361.html